Evidence map›Paper›PMID 39883454›Full record

ArticleJAMA2025

Molecular Phenotyping With Proteomics.

Devin K Schweppe, Brian J Beliveau, Andrew N Hoofnagle

Abstract read
In one paragraph

Article in JAMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Devin K SchweppeDepartment of Genome Sciences, University of Washington, Seattle.
Brian J BeliveauDepartment of Genome Sciences, University of Washington, Seattle.
Andrew N HoofnagleDepartment of Laboratory Medicine & Pathology, University of Washington, Seattle.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Project 4: Novel reagent development to enable molecular characterizationU19AG065156 · NIA · UNIVERSITY OF WASHINGTON · PI TIAN, LU · 2020 to 2024
$15.9M
Quantifying proteins in plasma do democratize personalized medicine for patients with type 1 diabetesU01DK137097 · NIDDK · UNIVERSITY OF WASHINGTON · PI ANDREW N HOOFNAGLE, Michael MacCoss · 2023 to 2026
$3.4M
Technology for evaluating drug-binding responses to small-molecule perturbationR35GM150919 · NIGMS · UNIVERSITY OF WASHINGTON · PI Devin Karl Schweppe · 2023 to 2026
$1.6M
NIA NIH HHS U19 AG065156NIDDK NIH HHS P30 DK017047NIDDK NIH HHS U01 DK137097NIGMS NIH HHS R35 GM150919
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39883454
PMCPMC12053805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.